Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies at ASCO GI 2016
Advertisement
[the_ad id="32629"]
Annual Meeting 2016 : Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies
By Editor